NCT04117230 CARDSUP - SWISS Circulatory Support Registry
| NCT ID | NCT04117230 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Cardiogenic Shock |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2019-08-09 |
| Primary Completion | 2034-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2019-08-09 with a primary completion date of 2034-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The project's main goal is to collect baseline clinical and procedural data as well as to assess clinical outcomes for all patients undergoing ECMO or Impella implantation at all included sites. All patients undergoing ECMO and/or IMPELLA implantation will be prospectively registered. Device use is according to the decision of the treating physician and independent of this registry.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years * Medical indication for implantation of a peripheral cannulated VA-ECMO or microaxial flow pump (IMPELLA) or newer LV / LA-Ascending Aorta devices. * Signed informed consent by patient or relative or waived consent by EC Exclusion Criteria: * None
Contact & Investigator
Lukas C Hunziker Munsch, Prof MD
STUDY CHAIR
University of Bern
Frequently Asked Questions
Who can join the NCT04117230 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiogenic Shock. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04117230 currently recruiting?
Yes, NCT04117230 is actively recruiting participants. Contact the research team at lukas.hunziker@insel.ch for enrollment information.
Where is the NCT04117230 trial being conducted?
This trial is being conducted at Basel, Switzerland, Bern, Switzerland, Lucerne, Switzerland, Winterthur, Switzerland and 1 additional location.
Who is sponsoring the NCT04117230 clinical trial?
NCT04117230 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Lukas C Hunziker Munsch, Prof MD at University of Bern. The trial plans to enroll 1,500 participants.